The low expression in active CD is indicative of NF-κB activation while the high expression of TRAFD1 in GFD patients is associated with the NF-κB pathway downregulation, as well as the decrease of the innate and adaptive immune response against gluten [19]. Here, NFKB1 is linked to gingival fibromatosis-progressive deafness syndrome.